Pfizer’s respiratory syncytial virus vaccine, called ABRYSVO, was approved by the US Food and Drug Administration on Wednesday. This is the second RSV vaccine that has been approved by the FDA for individuals above 60 years of age, the first being Arexvy, by GSK. The clinical trial of ABRYSVO involved roughly 37,000 participants and, according to a Pfizer press release, is expected to be available before the next peak RSV season in the fall. With over 60,000 older adults hospitalized each year due to RSV, the pharmaceutical industry has been seeking to develop a vaccine for the illness for more than half a century. Pfizer’s senior vice president and chief scientific officer of research and development, Annaliesa Anderson, calls the approval a monumental step toward alleviating RSV’s significant burden on higher-risk populations, particularly the older adults. The virus is highly transmissible, and those with compromised immune systems are at an increased risk of severe outcomes from the illness. Cases of RSV tend to be the highest between December and February, and in 2022, especially pediatric cases, were seen early in the fall, while cases peaked among patients aged 65 and older in early December, the highest rate since at least 2016.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
